Monthly Archives: May, 2023
Compass Health Center Launches OCD & Complex Anxiety Program for Children in Western Suburbs to Address Youth Mental Health Crisis
CHICAGO, May 2, 2023 (Newswire.com) - According to recent data collected by the Centers for Disease Control (CDC) between 2016-2019, more than 5.8 million children between the ages of 3-17 in the United States had been diagnosed with an anxiety disorder. These numbers have only increased since the start of the pandemic. In response to this need, Compass Health Center's Oak Brook location has opened its new Obsessive Compulsive Disorder (OCD) & Complex Anxiety Program for children ages 8-13.
This new program complements Compass's Adolescent program for ages 13-18 and supports children whose OCD and other more complex anxiety symptoms persistently interfere with daily functioning. In children, these diagnoses often present as refusal to leave home or attend school, refusal to participate in the classroom, excessive worry, sleep disturbances, and physical health concerns like chronic headaches and stomachaches.
"Since opening our doors to the child population in the West suburbs, we have seen the continued need for more specialized treatment when it comes to OCD and other anxiety disorders. We are excited to offer a more tailored approach to treating OCD and Anxiety with Exposure and Response Prevention (ERP). Having recently launched this specialty in our Adolescent Program, we have seen improved outcomes with these patients and their families and look forward to offering this to our child patients and families as well," said Katrina Shannon, LMFT, Director of Child and Adolescent Programs, Compass Health Center - Oak Brook.
Compass's evidence-based OCD and Complex Anxiety Partial Hospitalization (PHP) and Intensive Outpatient (IOP) programming introduces children to exposure therapy, one of the most effective treatments for OCD and other anxiety disorders, such as Separation Anxiety Disorder, Social Anxiety Disorder, and Panic Disorder. In addition to attending group and family therapy sessions, children in the program meet with dedicated exposure therapists to address their fears and the avoidance strategies the patients have adopted to manage their fears.
Children are taught to recognize the negative impact these avoidance strategies are having on their lives and are supported in gradually decreasing their avoidance behaviors. As the child slowly comes into contact with their fears, they learn to function in the presence of their fears and eventually to think about their fears differently. As part of Compass's individualized care model, children participate in family therapy with one or more of their family members, allowing for the family to learn how best to support their anxious child and how not to support their avoidance strategies.
Ninety percent of Compass's child program participants successfully complete the program and experience a significant reduction in anxiety symptoms. In addition, 95 percent of children in Compass programming avoid hospitalization due to mental health symptoms.
"We successfully treat these symptoms and diagnoses in our specialty programs for adolescents and adults in Oak Brook and for all ages at our other locations. We are excited to expand these services in a specialized way to children as young as 8 years old and their families in the communities served by our Oak Brook location," said Kerry Lusignan, LCSW, Chief Clinical Officer, Compass Health Center - Oak Brook.
Compass's expert clinical team of masters-level clinicians understands and focuses on the individualized approach to treatment, which helps children in moving towards achieving a meaningful and functional life. Learn more: https://compasshealthcenter.net/
Contact Information:Britt Teasdale
Associate Director, Brand Management, Compass Health Center
[email protected]
Phone 216-926-0550
Original Source: Compass Health Center Launches OCD & Complex Anxiety Program for Children in Western Suburbs to Address Youth Mental Health Crisis
Grand Funk Railroad Adds Dates to Highly Anticipated ‘The American Band Tour’
Grand Funk Railroad 'The American Band Tour' Ad Mat
Tour date poster for Grand Funk Railroad's \"The American Band Tour\"
NASHVILLE, Tenn., May 2, 2023 (Newswire.com) - Multi-platinum selling iconic group GRAND FUNK RAILROAD announced today additional tour dates to their highly anticipated upcoming 'The American Band Tour,' in honor of the 50th anniversary of their 1973 "We're An American Band" platinum-selling single and album. New dates include performances in New York, Ohio, Arizona, Kentucky, North Carolina, Oklahoma, Minnesota, Georgia, Pennsylvania, Utah, Nevada, Indiana, South Carolina, Missouri, Alabama, Louisiana, California, South Dakota, New Jersey, Michigan, and Mississippi.
One of rock's most definitive anthems, founding member Don Brewer (vocals and drums) was the soul writer and vocalist on "We're An American Band," which went all the way to #1 on the Billboard 'Hot 100' chart on Sept. 29, 1973.
"'We're An American Band' came to me when we were flying from town-to-town on our 'Phoenix Tour' in 1972," said Brewer of writing the song. "We were being sued by our former manager, Terry Knight, and he was trying to stop us from performing. The line, 'We're comin' to your town, we'll help you party it down,' came to me first, and I wrote the song around that line, taking snippets of things going on during the tour at that time - like staying up all night with Freddy King playing poker, four young chiquitas in Omaha, sweet, sweet Connie in Little Rock, and, finally, the declaration, 'We're An American Band,' because it sounds great and sings well."
As part of this year's itinerary, the legendary rock & roll powerhouse will be the "special guests" of Kid Rock for two hometown shows in Michigan at Little Caesars Arena on Friday, July 14, and Saturday, July 15. See GRAND FUNK RAILROAD's full tour itinerary below.
ABOUT GRAND FUNK RAILROAD:
Known as "The American Band," the high-energy five-piece group includes original founding members Don Brewer (vocals and drums, writer and singer of the multi-million selling hit, "We're an American Band") and bassist Mel Schacher, "The God of Thunder." Joining Don and Mel are true "All Stars." Singer Max Carl is a rock veteran from 38 Special. Max penned and sang 38's biggest hit "Second Chance" and was co-founder of California's legendary Jack Mack and the Heart Attack. Don refers to Max as "the best blue-eyed soul singer on the planet." Lead guitarist Bruce Kulick is best known for his 12 years with KISS and has credits with Michael Bolton, Meatloaf and Billy Squier. (KISS members Gene Simmons and Paul Stanley were influenced early on by Grand Funk.) Keyboardist Tim Cashion has a master's degree in music from the University of Miami. Affectionately called "Dr. Tim", his credits include stints with Bob Seger and the Silver Bullet Band and English soul man Robert Palmer.
Contact Information:Elise Anderson
Owner, Elicity Public Relations
[email protected]
(615) 946-6055
Related Files
(GFR) Additional Tour Dates Announce - FINAL.pdf
Original Source: Grand Funk Railroad Adds Dates to Highly Anticipated 'The American Band Tour'
Imagene Wins Frost & Sullivan’s Technology Innovation Leadership Award for Its Revolutionary AI-Based Molecular Testing for Cancer Diagnosis
Best Practices Award - Imagene
Imagene won the 2023 Technology Innovation Leadership Award in AI-based molecular testing for cancer diagnosis.
TEL AVIV, Israel, May 2, 2023 (Newswire.com) - Imagene, an emerging leader in the field of AI-based precision oncology, is proud to announce its win of the Frost & Sullivan 2023 Europe Technology Innovation Leadership Award in AI-based molecular testing for cancer diagnosis.
Frost & Sullivan Best Practices awards recognize companies for demonstrating outstanding achievement and superior performance in leadership and technological innovation. Imagene AI has been acknowledged for its groundbreaking technology and commitment to innovation and creativity in supporting physicians and patients.
Ashish Kaul, industry analyst at Frost & Sullivan, said, "Imagene's AI-based molecular testing technology scales to streamline cancer care processes and needs. It accelerates cancer diagnosis via accurate, image-based, immediate biomarker profiling, overcoming existing barriers and revolutionizing the market. Frost & Sullivan anticipates rapid, widespread technology adoption."
Imagene AI's technology can detect a wide range of cancer biomarkers in real-time, generating immediate genomic insights from digitized biopsy images alone. By reducing the time-to-results of molecular testing from several weeks to minutes, Imagene's AI-based solution transforms cancer diagnosis and advances precision medicine.
"We are honored to receive this prestigious award from Frost & Sullivan, which validates our dedication to delivering world-class AI-based molecular testing solutions for cancer diagnosis," said Dean Bitan, Co-founder and CEO of Imagene. "Our mission is to provide healthcare professionals with immediate and accurate biomarker profiling, empowering them with crucial information that enables optimal navigation in the complex cancer diagnosis process. This recognition affirms our commitment to innovation and to helping cancer patients in getting the most optimal treatment medicine can offer."
Frost & Sullivan recognizes the high value and accuracy levels of Imagene's AI-based molecular diagnosis solution and its strategic partnerships with leading medical centers and pharmaceutical companies worldwide. Imagene's technology also supports pharmaceutical companies' drug research and development activities, enabling optimal patient stratification for clinical trial optimization.
With its strong overall performance and dedication for bringing value to physicians and patients, Imagene AI is poised to set new market trends and address unmet needs in cancer care. The Frost & Sullivan 2023 Europe Technology Innovation Leadership Award recognizes Imagene's ongoing excellence and pioneering leadership role in the AI-based molecular testing for cancer diagnosis market.
About Imagene
Imagene is an emerging leader in the field of AI-based precision oncology, leveraging AI to profile, in real-time, a broad range of cancer biomarkers from a digitized biopsy image alone. Imagene's AI-based molecular diagnostic solutions streamline cancer care processes and accelerate cancer diagnosis through precise, image-based, immediate biomarkers profiling.
Imagene is an award-winning diverse BioMed startup with an experienced, passionate and bright team. Our success derives from our cutting-edge technology and multidisciplinary team of data scientists, biologists, software engineers, and medical experts. The company collaborates with top-tier medical centers and pharmaceutical companies worldwide.
For more information, visit www.imagene.ai.
About Frost & Sullivan
For six decades, Frost & Sullivan has been world-renowned for its role in helping investors, corporate leaders, and governments navigate economic changes and identify disruptive technologies, Mega Trends, new business models, and companies to action, resulting in a continuous flow of growth opportunities to drive future success. Contact us: Start the discussion.
Contact Information:Avital Rabani
Head of Marketing
[email protected]
Original Source: Imagene Wins Frost & Sullivan's Technology Innovation Leadership Award for Its Revolutionary AI-Based Molecular Testing for Cancer Diagnosis